Pembrolizumab and nivolumab are examples of anti-PD-1 monoclonal antibodies, while atezolizumab targets PD-L1, showcasing the breadth of strategies employed to bolster the immune system’s ability to fight cancer [36]. Here, CD274 is linked to cancer.